Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 3/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9592586 | 0.84 | PKMYT1 (0.36) | GRM5PKMYT1POLBLMNAPARP1 | |
| SCHEMBL24069013 | 0.82 | ALDH1A1 (0.37) | GRM5ALDH1A1TDP1 | |
| SCHEMBL28915362 | 0.82 | DGAT1 (0.43) | GRM5PKMYT1POLBLMNAPARP1 | |
| SCHEMBL18502145 | 0.80 | GRM5 (0.53) | GRM5PKMYT1POLBLMNAADORA2A | |
| SCHEMBL3460085 | 0.78 | SIRT3 (0.37) | GRM5POLBLMNAHTTADORA2A | |
| SCHEMBL27895760 | 0.78 | PLAU (0.44) | LMNAADORA2AADORA1ALDH1A1IKBKB | |
| SCHEMBL30509867 | 0.78 | SIRT3 (0.37) | GRM5POLBLMNAHTTADORA2A | |
| SCHEMBL13242156 | 0.77 | NPSR1 (0.48) | GRM5LMNAALDH1A1 | |
| SCHEMBL18779089 | 0.76 | PDPK1 (0.44) | GRM5PKMYT1POLBLMNAADORA2A | |
| Favipiravir SCHEMBL587913 | 0.76 | LCK (0.34) | LMNAADORA2AADORA1ALDH1A1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114507243-B | Isothiazolo heterocyclic compounds, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-05-14 | — | — | CN | disclosed |
| CN-113106130-B | Application of nitrile hydratase derived from staphylococcus aggregatus in preparation of amide pyrazine compounds | 核芯生物医药科技(杭州)有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-113025671-B | Application of nitrile hydratase derived from sinorhizobium meliloti in preparation of amide pyrazine compounds | 浙江恒康药业股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-114507243-A | Isothiazole heterocyclic compound, preparation method thereof, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-05-17 | — | — | CN | disclosed |
| WO-2021147235-A1 | APPLICATION OF FAVIPIRAVIR IN TREATING CORONAVIRUS INFECTION | 中国人民解放军军事科学院军事医学研究院 | 2021-07-29 | — | — | WO | disclosed |
| CN-113106130-A | Application of nitrile hydratase derived from staphylococcus aggregatus in preparation of amide pyrazine compounds | 浙江恒康药业股份有限公司 | 2021-07-13 | — | — | CN | disclosed |
| CN-113025671-A | Application of nitrile hydratase derived from sinorhizobium meliloti in preparation of amide pyrazine compounds | 浙江恒康药业股份有限公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-111662938-B | Application of nitrile hydratase in catalyzing hydration reaction of cyanopyrazine compound to generate amide pyrazine compound | 浙江恒康药业股份有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-111662938-A | Application of nitrile hydratase in catalyzing hydration reaction of cyanopyrazine compound to generate amide pyrazine compound | 浙江恒康药业股份有限公司 | 2020-09-15 | — | — | CN | disclosed |
| US-9181203-B2 | Substituted pyrazino[2,3-d]isooxazoles as intermediates for the synthesis of substituted pyrazinecarbonitriles and substituted pyrazinecarboxamides | FUJIFILM CORPORATION (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| CN-101835780-A | Imidazo [1,2-a ] pyrazine compounds for the treatment of viral infections such as hepatitis | BIOFOCUS DPI LTD | 2010-09-15 | — | — | CN | disclosed |
| EP-2193131-A2 | IMIDAZO[1,2-A]PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | Biofocus DPI Limited (GB) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009024585-A2 | IMIDAZO [1,2-A] PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | BIOFOCUS DPI LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024585-A2 | IMIDAZO [1,2-A] PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | BIOFOCUS DPI LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
| CN-100434079-C | Pyrazine nucleotide/pyrazine nucleoside analogue and medical application thereof | FUJIYAMA CHEMICAL IND CO LTD (JP) | 2008-11-19 | — | — | CN | disclosed |
| CN-1551777-A | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | 富山化学工业株式会社 | 2004-12-01 | — | — | CN | disclosed |
| US-20040235761-A1 | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1417967-A1 | NOVEL VIRUS PROLIFERATION INHIBITION/VIRUCIDAL METHOD AND NOVEL PYRADINE NUCLEOTIDE/PYRADINE NUCLEOSIDE ANALOGUE | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | CYP3A5, HAVCR2, CYP3A43 | GRM5 2656/4885PKMYT1 3335/4885POLB 1195/4885 |
| US-20040235761-A1 | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | CDK5, NT5C3B, CDK15 | GRM5 253/4885PKMYT1 1424/4885POLB 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.